THE Pharmaceutical Benefits Scheme (PBS) has confirmed that section 90 pharmacies can supply approved substitute benefits under the Therapeutic Goods Administration's (TGA's) Serious Scarcity Substitution Instrument (SSSI) for tocilizumab.
However, pharmacists dispensing the medication will be required to record the information justifying the supply of the substitute under the SSSI in writing.
Pharmacists will also be required to inform the prescriber in writing that the substitute benefit was made within 72 hours of supply to the patient
Additionally, pharmacists will also be required to identify and dispense against the item code for the substitute benefit.
CLICK HERE for more.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Aug 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Aug 21
